| AC IMMUNE SA SF-,02 |
| Schweiz |
| Gesundheit |
| CH0329023102 / A2AR5F |
| IMR (Frankfurt) / ACIU (NASDAQ) |
| FRA:IMR, ETR:IMR, IMR:GR, NASDAQ:ACIU |
| - |
| https://www.acimmune.com/ |
|
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company des..
>Volltext.. |
| 245.99 Mio. EUR |
| 152.67 Mio. EUR |
| 3.71 Mio. EUR |
| -69.08 Mio. EUR |
| -73.28 Mio. EUR |
| -0.73 EUR |
| 4.97 Mio. EUR |
| 29.3 Mio. EUR |
| -75.08 Mio. EUR |
| 0.97 |
| -88.02% |
| -30.25% |
| - |
| - |
| - |
| - |
| AC IMMUNE |
| 06.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|